Publications searcher The science produced by our scientists is very important. In 2024, 1,501 papers were published in scientific journals with an average impact factor of over 7.13 points. Fulltext search Alphabetic A-Z Alphabetic Z-A Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada. PMID: 31159865 Journal: BMC Pharmacology & Toxicology Year: 2019 Reference: BMC Pharmacol Toxicol. 2019 Jun 3;20(1):37. doi: 10.1186/s40360-019-0302-1. Impact factor: Publication type: Paper in international publication Authors: Aznar, Maria Luisa; Brode, Sarah K; Elshal, Ahmed Said; Marras, Theodore K; Mehrabi, Mahtab et al. DOI: 10.1186/s40360-019-0302-1 Safety and effectiveness of sodium colistimethate-loaded nanostructured lipid carriers (SCM-NLC) against P. aeruginosa: in vitro and in vivo studies following pulmonary and intramuscular administration. PMID: 30849549 Journal: Nanomedicine-Nanotechnology Biology and Medicine Year: 2019 Reference: Nanomedicine. 2019 Jun;18:101-111. doi: 10.1016/j.nano.2019.02.014. Epub 2019 Mar 6. Impact factor: 5.57 Publication type: Paper in international publication Authors: Aguirre, J J, Esquisabel, A, Igartua, M, Gainza, E, Hernandez, R M, Gavalda, J, Pedraz, J L, Gutierrez, F B, Bachiller, D, Fleischer, A et al. DOI: 10.1016/j.nano.2019.02.014 Safety and effectiveness of sodium colistimethate-loaded nanostructured lipid carriers (SCM-NLC) against P. aeruginosa: in vitro and in vivo studies following pulmonary and intramuscular administration. PMID: 30849549 Journal: Nanomedicine-Nanotechnology Biology and Medicine Year: 2019 Reference: Nanomedicine. 2019 Jun;18:101-111. doi: 10.1016/j.nano.2019.02.014. Epub 2019 Mar 6. Impact factor: Publication type: Paper in international publication Authors: Aguirre, J J; Bachiller, D; Basas, J; Esquisabel, A; Fleischer, A; Gainza, E; Gainza, G; Gavalda, J; Gomis, X; Gutierrez, F B et al. DOI: 10.1016/j.nano.2019.02.014 Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients. PMID: 30446802 Journal: ANNALS OF HEMATOLOGY Year: 2019 Reference: Ann Hematol. 2019 Feb;98(2):321-330. doi: 10.1007/s00277-018-3507-2. Epub 2018 Nov 16. Impact factor: 2.85 Publication type: Paper in international publication Authors: Claudiani, Simone, Garcia-Gutierrez, Valentin, Milojkovic, Dragana, Hernandez-Boluda, Juan Carlos, Ramirez, Maria Jose, Romero, Esperanza, Romo, Andres, Rosell, Ana, Saavedra, Silvanna Saavedra, Sebrango, Ana et al. DOI: 10.1007/s00277-018-3507-2 Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients. PMID: 30446802 Journal: ANNALS OF HEMATOLOGY Year: 2019 Reference: Ann Hematol. 2019 Feb;98(2):321-330. doi: 10.1007/s00277-018-3507-2. Epub 2018 Nov 16. Impact factor: Publication type: Paper in international publication Authors: Amustio Diez, Elena; Boque, Concepcion; Carrascosa, Guiomar Bautista; Casado-Montero, Luis Felipe; Claudiani, Simone; De Las Heras Rodriguez, Natalia; Del Carmen Garcia Garay, Maria; Fernandez, Maria Angeles; Garcia, Abelardo Barez; Garcia-Gutierrez, Valentin et al. DOI: 10.1007/s00277-018-3507-2 Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase 2 clinical trial. PMID: 30978502 Journal: Journal of Thoracic Oncology Year: 2019 Reference: J Thorac Oncol. 2019 Jul;14(7):1266-1276. doi: 10.1016/j.jtho.2019.03.020. Epub 2019 Apr 9. Impact factor: 12.46 Publication type: Paper in international publication Authors: Schildhaus, Hans-Ulrich, Franklin, Jeremy, Sebastian, Martin, Felip, Enriqueta, Grohe, Christian, Rodriguez-Abreu, Delvys, Abdulla, Diana S Y, Bischoff, Helge, Brandts, Christian, Carcereny, Enric et al. DOI: 10.1016/j.jtho.2019.03.020 Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase 2 clinical trial. PMID: 30978502 Journal: Journal of Thoracic Oncology Year: 2019 Reference: J Thorac Oncol. 2019 Jul;14(7):1266-1276. doi: 10.1016/j.jtho.2019.03.020. Epub 2019 Apr 9. Impact factor: Publication type: Paper in international publication Authors: Abdulla, Diana S Y; Bischoff, Helge; Brandts, Christian; Buttner, Reinhard; Carcereny, Enric; Corral, Jesus; Dingemans, Anne-Marie C; Fassunke, Jana; Felip, Enriqueta; Fischer, Rieke N et al. DOI: 10.1016/j.jtho.2019.03.020 Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. PMID: 30383184 Journal: JAMA Oncology Year: 2019 Reference: JAMA Oncol. 2019 Feb 1;5(2):195-203. doi: 10.1001/jamaoncol.2018.4628. Impact factor: 22.416 Publication type: Paper in international publication Authors: Mesia, Ricard, Siu, Lillian L, Even, Caroline, Delord, Jean-Pierre, Krauss, Jurgen, Saba, Nabil F, Nabell, Lisle, Ready, Neal E, Brana, Irene, Kotecki, Nuria et al. DOI: 10.1001/jamaoncol.2018.4628 Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. PMID: 30383184 Journal: JAMA Oncology Year: 2019 Reference: JAMA Oncol. 2019 Feb 1;5(2):195-203. doi: 10.1001/jamaoncol.2018.4628. Impact factor: Publication type: Paper in international publication Authors: Armstrong, Jon M; Bonomi, Marcelo; Brana, Irene; Daste, Amaury; Delord, Jean-Pierre; Even, Caroline; Fayette, Jerome; Gilbert, Jill; Jarkowski, Anthony; Kotecki, Nuria et al. DOI: 10.1001/jamaoncol.2018.4628 Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). PMID: 31581055 Journal: EUROPEAN JOURNAL OF CANCER Year: 2019 Reference: Eur J Cancer. 2019 Nov;121:144-153. doi: 10.1016/j.ejca.2019.08.014. Epub 2019 Sep 30. Impact factor: 6.68 Publication type: Paper in international publication Authors: Hoeller, Christoph, Schadendorf, Dirk, Ascierto, Paolo A, Haanen, John, Espinosa, Enrique, Demidov, Lev, Garbe, Claus, Guida, Michele, Lorigan, Paul, Chiarion-Sileni, Vanna et al. DOI: 10.1016/j.ejca.2019.08.014 Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). PMID: 31581055 Journal: EUROPEAN JOURNAL OF CANCER Year: 2019 Reference: Eur J Cancer. 2019 Nov;121:144-153. doi: 10.1016/j.ejca.2019.08.014. Epub 2019 Sep 30. Impact factor: Publication type: Paper in international publication Authors: Ascierto, Paolo A; Bafaloukos, Dimitrios; Chiarion-Sileni, Vanna; Demidov, Lev; Dummer, Reinhard; Espinosa, Enrique; Fierro, Maria Teresa; Garbe, Claus; Gogas, Helen; Grigoryeva, Elena et al. DOI: 10.1016/j.ejca.2019.08.014 Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). PMID: 31445199 Journal: EUROPEAN JOURNAL OF CANCER Year: 2019 Reference: Eur J Cancer. 2019 Sep;119:168-178. doi: 10.1016/j.ejca.2019.07.010. Epub 2019 Aug 21. Impact factor: 6.68 Publication type: Paper in international publication Authors: Gutzmer, Ralf, Nathan, Paul, Ascierto, Paolo A, Haanen, John, Espinosa, Enrique, Demidov, Lev, Garbe, Claus, Guida, Michele, Lorigan, Paul, Chiarion-Sileni, Vanna et al. DOI: 10.1016/j.ejca.2019.07.010 Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). PMID: 31445199 Journal: EUROPEAN JOURNAL OF CANCER Year: 2019 Reference: Eur J Cancer. 2019 Sep;119:168-178. doi: 10.1016/j.ejca.2019.07.010. Epub 2019 Aug 21. Impact factor: Publication type: Paper in international publication Authors: Ascierto, Paolo A; Bafaloukos, Dimitrios; Chiarion-Sileni, Vanna; Demidov, Lev; Dummer, Reinhard; Espinosa, Enrique; Fierro, Maria Teresa; Garbe, Claus; Gogas, Helen; Grigoryeva, Elena et al. DOI: 10.1016/j.ejca.2019.07.010 Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. PMID: 31487218 Journal: JOURNAL OF CLINICAL ONCOLOGY Year: 2019 Reference: J Clin Oncol. 2019 Nov 1;37(31):2825-2834. doi: 10.1200/JCO.19.00739. Epub 2019 Sep 5. Impact factor: 28.245 Publication type: Paper in international publication Authors: Naumann, R Wendel, Hollebecque, Antoine, Meyer, Tim, Devlin, Michael-John, Oaknin, Ana, Kerger, Joseph, Lopez-Picazo, Jose M, Machiels, Jean-Pascal, Delord, Jean-Pierre, Evans, Thomas R J et al. DOI: 10.1200/JCO.19.00739 Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. PMID: 31487218 Journal: JOURNAL OF CLINICAL ONCOLOGY Year: 2019 Reference: J Clin Oncol. 2019 Nov 1;37(31):2825-2834. doi: 10.1200/JCO.19.00739. Epub 2019 Sep 5. Impact factor: Publication type: Paper in international publication Authors: Boni, Valentina; Calvo, Emiliano; Chen, Tian; Delord, Jean-Pierre; Devlin, Michael-John; Evans, Thomas R J; Gu, Junchen; Hollebecque, Antoine; Kerger, Joseph; Li, Bin et al. DOI: 10.1200/JCO.19.00739 Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. PMID: 31285147 Journal: LANCET NEUROLOGY Year: 2019 Reference: Lancet Neurol. 2019 Sep;18(9):845-856. doi: 10.1016/S1474-4422(19)30137-1. Epub 2019 Jul 5. Impact factor: 28.755 Publication type: Paper in international publication Authors: Rudick, Richard, Cadavid, Diego, Mellion, Michelle, Hupperts, Raymond, Edwards, Keith R, Calabresi, Peter A, Drulovic, Jelena, Giovannoni, Gavin, Hartung, Hans-Peter, Arnold, Douglas L et al. DOI: 10.1016/S1474-4422(19)30137-1 Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. PMID: 31285147 Journal: LANCET NEUROLOGY Year: 2019 Reference: Lancet Neurol. 2019 Sep;18(9):845-856. doi: 10.1016/S1474-4422(19)30137-1. Epub 2019 Jul 5. Impact factor: Publication type: Paper in international publication Authors: Aguera Morales, Eduardo; Al Khedr, Abdullatif; Ampapa, Radek; Arnold, Douglas L; Arroyo, Rafael; Belkin, Martin; Bonek, Robert; Boyko, Alexey; Cadavid, Diego; Calabresi, Peter A et al. DOI: 10.1016/S1474-4422(19)30137-1 Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. PMID: 31492652 Journal: LANCET NEUROLOGY Year: 2019 Reference: Lancet Neurol. 2019 Nov;18(11):1021-1033. doi: 10.1016/S1474-4422(19)30238-8. Epub 2019 Sep 3. Impact factor: 28.755 Publication type: Paper in international publication Authors: Cohen, Jeffrey A, Comi, Giancarlo, Selmaj, Krzysztof W, Bar-Or, Amit, Arnold, Douglas L, Steinman, Lawrence, Hartung, Hans-Peter, Montalban, Xavier, Kubala Havrdova, Eva, Cree, Bruce A C et al. DOI: 10.1016/S1474-4422(19)30238-8 Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. PMID: 31492652 Journal: LANCET NEUROLOGY Year: 2019 Reference: Lancet Neurol. 2019 Nov;18(11):1021-1033. doi: 10.1016/S1474-4422(19)30238-8. Epub 2019 Sep 3. Impact factor: Publication type: Paper in international publication Authors: Arnold, Douglas L; Bar-Or, Amit; Cohen, Jeffrey A; Comi, Giancarlo; Cree, Bruce A C; Hartung, Hans-Peter; Huang, Vivian; Kappos, Ludwig; Kubala Havrdova, Eva; Minton, Neil et al. DOI: 10.1016/S1474-4422(19)30238-8 Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. PMID: 31492651 Journal: LANCET NEUROLOGY Year: 2019 Reference: Lancet Neurol. 2019 Nov;18(11):1009-1020. doi: 10.1016/S1474-4422(19)30239-X. Epub 2019 Sep 3. Impact factor: 28.755 Publication type: Paper in international publication Authors: Cree, Bruce A C, Sheffield, James K, Minton, Neil, Raghupathi, Kartik, Ding, Ning, Cohen, Jeffrey A, Kubala Havrdova, Eva, Montalban, Xavier, Steinman, Lawrence, Comi, Giancarlo et al. DOI: 10.1016/S1474-4422(19)30239-X Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. PMID: 31492651 Journal: LANCET NEUROLOGY Year: 2019 Reference: Lancet Neurol. 2019 Nov;18(11):1009-1020. doi: 10.1016/S1474-4422(19)30239-X. Epub 2019 Sep 3. Impact factor: Publication type: Paper in international publication Authors: Arnold, Douglas L; Bar-Or, Amit; Cohen, Jeffrey A; Comi, Giancarlo; Cree, Bruce A C; Ding, Ning; Hartung, Hans-Peter; Kappos, Ludwig; Kubala Havrdova, Eva; Minton, Neil et al. DOI: 10.1016/S1474-4422(19)30239-X Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. PMID: 31446994 Journal: LUNG CANCER Year: 2019 Reference: Lung Cancer. 2019 Sep;135:188-195. doi: 10.1016/j.lungcan.2019.07.004. Epub 2019 Jul 8. Impact factor: 4.599 Publication type: Paper in international publication Authors: Nosaki, Kaname, Saka, Hideo, Hosomi, Yukio, Baas, Paul, de Castro, Gilberto Jr, Reck, Martin, Wu, Yi-Long, Brahmer, Julie R, Felip, Enriqueta, Sawada, Takeshi et al. DOI: 10.1016/j.lungcan.2019.07.004 Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. PMID: 31446994 Journal: LUNG CANCER Year: 2019 Reference: Lung Cancer. 2019 Sep;135:188-195. doi: 10.1016/j.lungcan.2019.07.004. Epub 2019 Jul 8. Impact factor: Publication type: Paper in international publication Authors: Baas, Paul; Brahmer, Julie R; de Castro, Gilberto Jr; Felip, Enriqueta; Han, Shi Rong; Hosomi, Yukio; Kush, Debra A; Lopes, Gilberto; Noguchi, Kazuo; Nosaki, Kaname et al. DOI: 10.1016/j.lungcan.2019.07.004 Safety and efficacy of prolonged use of dalbavancin in bone and joint infections. PMID: 30858217 Journal: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY Year: 2019 Reference: Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: AAC.02280-18. doi: 10.1128/AAC.02280-18. Print 2019 May. Impact factor: 4.715 Publication type: Paper in international publication Authors: Arroyo, A, Barbero, J M, Cuadra, F, Del Arco, A, Del Toro, M D, Guio, L, Jimenez-Beatty, D, Lois, N, Martin, O, Martinez Alvarez, R M et al. DOI: 10.1128/AAC.02280-18 Pagination First page « First Previous page ‹ Previous … Page 778 Page 779 Page 780 Page 781 Current page 782 Page 783 Page 784 Page 785 Page 786 … Next page Next › Last page Last »
